Year: 2019

Le capitaine Michael Ott de Phoenix Air Group, Inc. a fait preuve d’un leadership exceptionnel en matière de sécurité durant une riche carrière de 35 ansCette distinction salue les efforts exceptionnels d’amélioration de la sécurité aérienne dans toute l’industriePlus de 450 professionnels de l’aviation ont assisté à la remise du prix au 23e colloque annuel Safety Standdown de BombardierFORT WORTH, Texas, 14 nov. 2019 (GLOBE NEWSWIRE) — Michael Ott a remporté le prestigieux prix Safety Standdown 2019 de Bombardier, sélectionné par les membres du conseil consultatif de Safety Standdown. Le capitaine Ott est directeur des contrats gouvernementaux ainsi que capitaine et pilote instructeur en chef à l’internationale pour le fournisseur mondial de services d’ambulance aérienne Phoenix Air Group, Inc. Le prix lui a été remis au 23e colloque...

LAKE FOREST, Calif, Nov. 14, 2019 (GLOBE NEWSWIRE) — ToughBuilt Industries, Inc. (“ToughBuilt”) (NASDAQ: TBLT; TBLTW; TBLTU), a leading designer, manufacturer and distributor of innovative tools and accessories for the building and home improvement industries, today announced that its Series B Warrants will expire on November 14, 2019 and December 17, 2019.Expiration of ToughBuilt Series B WarrantsAll outstanding Series B Warrants to purchase common stock of ToughBuilt will expire on Thursday November 14, 2019 and December 17, 2019. Series B Warrants were issued as a component of the Class A Units during ToughBuilt’s initial public offering and concurrent private placement in November 2018, with a smaller amount issued during the greenshoe portion of the IPO in December 2018.Series B Warrants issued during the November 2018 IPO...

Company announcement – No. 38 / 2019Zealand Pharma completes Phase 3 clinical program for HypoPal®rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment

Presentation to Focus on the Company’s MVA-VLP Platform for Safe and Effective Vaccines for Infectious Diseases and CancerATLANTA, GA, Nov. 14, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will be a featured speaker at the Vaccines Research and Development conference, being held November 18-20, 2019 in Boston, Massachusetts.  Dr. Guirakhoo will co-chair a session on infectious diseases, during which he will deliver a presentation entitled, MVA as a Safe and Effective Platform for Delivery of Multi-Antigen Vaccine Candidates for Infectious Diseases and Cancer. During the conference, Dr. Guirakhoo will also serve as a panelist for a session discussing the...

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) — LogMeIn, Inc. (Nasdaq:LOGM) today announced it has been named one of the Top 100 Workplaces in Utah by The Salt Lake Tribune. The annual list measures aspects of companies’ workplace culture beyond benefits and perks, including alignment, execution and connection. The awards are based on anonymous employee feedback gathered through a third-party survey administered by Energage, the research partner behind the Top Workplaces program.“As LogMeIn continues to grow, we prioritize creating a dynamic environment where all our employees feel valued, challenged and able to do the best work of their career,” said Jo Deal, Chief Human Resources Officer at LogMeIn. “Our people are what fuel LogMeIn’s growth and innovation and make up our diverse, collaborative and fun culture. It’s rewarding to know...

 The public company ŽEMAITIJOS PIENAS, upon becoming on a transaction basis the sole shareholder of the private limited liability company Baltijos Mineralinių Vandenų Kompanija (see an announcement within the Nasdaq announcement system)[1] having been transformed into the public company based on the sole shareholder’s decision of 25 September 2019, informs that it was resolved by decision of the sole shareholder of the public company Baltijos Mineralinių Vandenų Kompanija held on 14 November 2019 :1. to reorganise the public company Baltijos Mineralinių Vandenų Kompanija that will cease its existence as a legal entity after the reorganisation by merging it with the public company ŽEMAITIJOS PIENAS for participation in the reorganisation by means of merger, by being acquired by the public company ŽEMAITIJOS PIENAS, legal entity code 180240752,...

WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London Healthcare Conference on November 21 at 2:40 p.m. GMT (9:40 a.m. EST).The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.  About Minerva NeurosciencesMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117,...

BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 5:20 p.m. GMT (12:20 p.m. EST).A live audio webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks...